FTC Moves To Squash $3.1B CLS-Talecris Merger
The Federal Trade Commission has officially moved to block blood plasma-derived therapeutics company CSL Ltd.'s proposed $3.1 billion acquisition of rival Talecris Biotherapeutics, a deal the agency claims will reduce competition...To view the full article, register now.
Already a subscriber? Click here to view full article